GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
0.5389
+0.0424 (8.54%)
At close: Feb 6, 2026, 4:00 PM EST
0.5301
-0.0088 (-1.63%)
After-hours: Feb 6, 2026, 7:56 PM EST

GT Biopharma Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Equivalents
2.533.951.085.678.975.3
Short-Term Investments
--12.8910.8423.01-
Cash & Short-Term Investments
2.533.9513.9716.5131.985.3
Cash Growth
-60.61%-71.72%-15.36%-48.38%503.72%18817.86%
Prepaid Expenses
0.940.190.080.050.190.36
Restricted Cash
0.090.09----
Total Current Assets
4.324.2314.0616.5632.175.66
Property, Plant & Equipment
--0.050.17--
Other Long-Term Assets
---0.01--
Total Assets
4.324.2314.1116.7432.175.66
Accounts Payable
0.773.854.333.148.192.24
Accrued Expenses
0.41.81.21.671.96.13
Short-Term Debt
----0.0326.33
Current Portion of Leases
--0.060.11--
Other Current Liabilities
0.150.251.050.020.140.38
Total Current Liabilities
1.325.96.634.9410.2635.09
Long-Term Leases
---0.06--
Total Liabilities
1.325.96.63510.2635.09
Common Stock
0.01000.030.030.01
Additional Paid-In Capital
703.77693.55689.54686.17674.35566.36
Retained Earnings
-700.78-695.23-682.07-674.47-653.58-595.8
Comprehensive Income & Other
----1.11-
Total Common Equity
3-1.677.4811.7321.91-29.44
Shareholders' Equity
3-1.677.4811.7321.91-29.43
Total Liabilities & Equity
4.324.2314.1116.7432.175.66
Total Debt
--0.060.170.0326.33
Net Cash (Debt)
2.533.9513.9116.3331.95-21.04
Net Cash Growth
-60.61%-71.60%-14.82%-48.87%--
Net Cash Per Share
0.892.0810.3215.3834.04-143.92
Filing Date Shares Outstanding
10.642.231.381.231.070.95
Total Common Shares Outstanding
6.052.231.381.091.070.17
Working Capital
3-1.677.4211.6221.91-29.43
Book Value Per Share
0.50-0.755.4110.7620.50-169.23
Tangible Book Value
3-1.677.4811.7321.91-29.44
Tangible Book Value Per Share
0.50-0.755.4110.7620.50-169.23
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q